The prodrug in abzyme therapy is:
Abzyme-directed enzyme prodrug therapy ADEPT-like strategy employs two-step approach achieving localized drug activation minimizing systemic exposure toxicity. First step abzyme engineered single-chain variable fragment fused tumor-targeting antibody anti-CEA or anti-HER2 or PEGylated enhancing permeability retention leaky tumor vasculature poor lymphatic drainage accumulates tumor interstitium reaching micromolar concentration while blood levels decline rapidly clearance liver kidney. Abzyme remains enzymatically active non-toxic alone because mammalian substrates lacking scissile bond recogn
Ref: Bagshawe ADEPT Abzyme Prodrug Activation Review 1994; PMC Abzyme Prodrug Therapy Targeted Release Mechanism 2020; Nature Biotech Abzyme Directed Therapy Concept Paper.
